# NexCure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nexcure

- Industry: Healthcare
- Headquarters: Boston, US
- Website: www.nexcure.com
- Total disclosed funding: $19M
- Latest round: Series A (Mar 5, 2026)
- Investors on record: 3

## About

NexCure LLC, headquartered in Boston, US, specializes in enhancing accessibility to advanced cancer therapies by developing outpatient treatment centers focused on CAR-T and T-cell engager therapies. Founded in 2024 by President & CEO and co-founder Michael Richman, NexCure LLC operates outpatient treatment centers that provide advanced cancer therapies. The company has undergone significant operational strategies to address healthcare gaps, particularly in regions lacking specialized cancer treatment facilities. Recently, on March 5, 2026, NexCure raised USD 19.00 mn in a Series A funding round led by RA Capital, with participation from Cencora Ventures and Oncology Ventures, totaling USD 19.00 mn raised. The founder's details are currently unavailable.NexCure focuses on expanding access to advanced cancer therapies, primarily through the development and operation of outpatient treatment centers specializing in CAR-T and T-cell engager therapies. Their core offerings integrate a platform that utilizes AI-powered patient selection, remote monitoring, and standardized clinical protocols, ensuring that each patient receives personalized care. The company addresses critical gaps in the healthcare infrastructure, particularly where specialized cancer treatment centers are limited, and aims to improve treatment accessibility and outcomes by providing these services closer to patients' homes. Their primary clients include health systems across various regions in the United States, where they aim to establish a network of outpatient centers to facilitate the delivery of these therapies.NexCure's revenue structure is based on partnerships with health systems to create outpatient treatment centers that facilitate the administration of advanced cancer therapies. Revenue is generated through service fees associated with treatments provided at these centers, typically involving direct payments from healthcare providers for administering CAR-T therapies, alongside potential revenue-sharing agreements based on treatment volumes.In March 2026, NexCure LLC raised USD 19.00 mn in Series A funding to build and operate outpatient clinics and supporting technology for delivering CAR-T and other complex therapies in community-based outpatient settings. The company plans to expand its reach by establishing new outpatient centers in additional regions, enhancing access to its advanced cancer therapies across the United States.

## Funding rounds

- Series A, Mar 5, 2026, $19M — RA Capital Management, Oncology Ventures, Cencora Ventures

## Investors

- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A
- Oncology Ventures (https://capitalatlas.ai/funds/oncology-ventures) — Series A
- Cencora Ventures (https://capitalatlas.ai/funds/cencora-ventures) — Series A